CivicaScript® Launches Affordable Biosimilar for Chronic Inflammatory Conditions

CivicaScript® Expands Access to Affordable Healthcare

CivicaScript®, a nonprofit organization based in Lehi, Utah, is on a mission to make essential medicines affordable and accessible to all. As part of this initiative, they have announced the distribution of a new biosimilar, ustekinumab-aauz, specifically designed for treating chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

What is Ustekinumab-aauz?

Ustekinumab-aauz is a human monoclonal antibody targeting cytokines interleukin-12 and interleukin-23, crucial components in inflammatory and immune responses. The introduction of this biosimilar is set to begin on January 1, 2026, and it represents a significant step forward in CivicaScript's efforts to diversify their rapidly expanding product portfolio. The move to include biosimilars in their offerings aligns with their goal to improve the accessibility of treatment options for patients suffering from these chronic diseases.

Pricing and Availability

CivicaScript will offer ustekinumab-aauz in prefilled syringes, available in two strengths: a 90 mg supply priced at $985 and a 45 mg supply at $575 for a 12-week duration. This pricing reflects CivicaScript’s commitment to transparency, allowing patients and healthcare providers to benefit from lower costs without sacrificing quality. The biosimilar will be exclusively available through CivicaScript’s network of members and partners, including health plans and pharmacy benefit managers, fostering greater accessibility and affordability for patients.

CivicaScript's Mission and Vision

Brent J. Eberle, President of CivicaScript, expressed the organization’s pride in launching ustekinumab-aauz, stating, "This significant development aligns with our mission to reduce financial burdens on patients and the healthcare system. We anticipate that this will be the first of many biosimilars offered in the upcoming years." CivicaScript’s non-profit status underscores its purpose to promote community health and welfare through affordable medication solutions.

The Impact of Biosimilars

Biosimilars like ustekinumab-aauz can greatly enhance treatment options by providing cost-effective alternatives to expensive biologics. This means that more patients will have access to effective therapies that were previously unaffordable due to high costs. The introduction of biosimilars plays a pivotal role in the future of healthcare, driving competition and innovation while protecting the financial interests of both patients and providers.

Conclusion

CivicaScript’s addition of ustekinumab-aauz to its portfolio not only highlights their innovative approach to healthcare solutions but also represents a broader shift towards affordable medication access. This initiative ensures that patients with chronic inflammatory conditions can receive the necessary treatments without facing exorbitant costs. As CivicaScript continues to expand its offerings, the healthcare landscape may witness a more equitable framework for medication accessibility, underscoring the importance of affordable solutions in improving health outcomes for all.

For further information on CivicaScript and its commitment to transparency in the drug supply chain, visit their website.